November 2025 in “Cancer Management and Research” Targeting Keratin 17 may help overcome cancer therapy resistance.
July 2013 in “Science-business Exchange” Blocking SEPT4 might help heal wounds and regrow hair faster.
21 citations
,
July 2011 in “Journal of the American Academy of Dermatology” A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.
8 citations
,
September 2017 in “Scientific Reports” MAD2B slows down the growth of skin cells that are important for hair development by interacting with TCF4.
January 2026 in “Clinical and Experimental Dermatology” Ruxolitinib helped a patient with alopecia areata regrow hair.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
14 citations
,
August 2009 in “Cancer epidemiology” AHCC reduces hair loss and liver injury caused by chemotherapy in rodents.
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
54 citations
,
September 2012 in “Acta ophthalmologica” Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.
January 2025 in “Cell Communication and Signaling” CXXC5 can both suppress and promote cancer, making it a complex target for treatment.
9 citations
,
May 2013 in “JAMA Dermatology” A woman's hair turned white after taking a cancer drug called dasatinib.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” SETDB1 is essential for controlling DNA methylation, silencing retrotransposons, and maintaining skin cell health, with its absence leading to skin inflammation and hair loss.
7 citations
,
January 2009 in “BMJ Case Reports” Gefitinib can cause slower, finer, brittle, and curly scalp hair.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
76 citations
,
February 2007 in “Cancer Research” Protein Kinase Cε increases skin sensitivity to UV damage and skin cancer risk.
4 citations
,
May 2020 in “PLOS ONE” Ingenol mebutate gel changes gene expression related to skin development and immune response in actinic keratosis.
5 citations
,
February 2017 in “Biomolecules & Therapeutics” 4-O-Methylhonokiol helps protect skin cells from growth-stopping effects of a protein by regulating growth-related pathways.
54 citations
,
February 1994 in “Journal of Investigative Dermatology” 219 citations
,
July 1995 in “PubMed” Keratinocyte growth factor promotes hair growth and reduces hair loss from chemotherapy.
2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
14 citations
,
October 2003 in “Annals of Oncology” About half the patients treated with capecitabine and docetaxel developed severe hand-foot syndrome.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.
97 citations
,
March 2002 in “Molecular and cellular biology” Mutant CDP/Cux protein causes hair defects and reduced male fertility in mice.
1 citations
,
January 2024 in “ACS Medicinal Chemistry Letters” TYK2 inhibitors show promise for treating cancer and autoimmune disorders.
14 citations
,
March 2015 in “Stem Cell Research & Therapy” ABCG2 protein marks stem-like skin cells in human epidermis.
8 citations
,
August 2018 in “BMJ Case Reports” Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
31 citations
,
March 2014 in “Journal of the European Academy of Dermatology and Venereology” BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.
April 2016 in “Journal of Investigative Dermatology” Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
22 citations
,
May 2011 in “Molecular Biology of the Cell” Integrin-linked kinase is crucial for normal skin healing.